학술논문
The FDA-approved compound, pramipexole and the clinical-stage investigational drug, dexpramipexole, reverse chronic allodynia from sciatic nerve damage in mice, and alter IL-1β and IL-10 expression from immune cell culture
Document Type
Article
Author
Source
In Neuroscience Letters 25 September 2023 814
Subject
Language
ISSN
0304-3940